N/A
Completed N=10
Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis
Source: ClinicalTrials.gov NCT01983787 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Oct 2015
Primary outcomePrimary: Blood-plasma Concentration of Piperacillin — 21; 21 mg/L
Summary
At the Department of Infectious Diseases, Aarhus University Hospital, continuous infusion with piperacillin/tazobactam for a period of 2 weeks, has been used for several years in patients with cystic fibrosis, suffering from acute pulmonary exacerbations (APE).
It is an outpatient treatment. To assess the efficacy and quality of the treatment, a blood test every 3rd day is taken to determine the concentration of Piperacillin in blood-plasma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood-plasma Concentration of Piperacillin |
21; 21 | — |
| SECONDARY The Time Above the Minimum Inhibitory Concentration (T>MIC) |
100; 100; 75; 75; 100; 100 | — |
| SECONDARY MIC of Pathogen Detected in Sputum Sample, Prior to Initiation of Treatment. |
3; 8; 16; 3; 0.5; 3 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with Cystic Fibrosis, suffering from acute pulmonary exacerbations, treated with continuous infusion of Piperacillin/Tazobactam for a period of two weeks.
Exclusion Criteria
- Age under 18
Data sourced from ClinicalTrials.gov (NCT01983787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.